News | June 02, 2015

Landmark Study Compares Traditional Defibrillators With Subcutaneous Models

First U.S. patients enrolled in international trial to evaluate implanted defibrillator that offers protection with less risk to the heart

PRAETORIAN trial, first U.S. patients, ICD, subcutaneous, S-ICD, defibrillators

June 2, 2015 — The Valley Hospital has been selected as the United States Coordinating Center for the international PRAETORIAN trial analyzing implantable cardioverter-defibrillators (ICDs). The trial will compare traditional ICDs with a newer model that may reduce the risk of complications associated with these otherwise life-saving devices.

Although ICDs have been used for decades to safeguard patients deemed at high risk for sudden death due to a heart rhythm disorder (arrhythmia), the traditional model relies on a transvenous electrode or lead placed in the heart. A major drawback of these ICDs has been the lead, which can break, become infected, or injure the heart and surrounding blood vessels. The alternative is a newer form of ICD, called a subcutaneous or S-ICD, that is implanted entirely under the skin without entering the heart or blood vessels. Valley was one of the first hospitals in New Jersey and one of only three hospitals in the tri-state area to have early experience with the S-ICD.

“Both types of ICDs have been shown to reduce the risk of sudden death,” says Suneet Mittal, M.D., director of electrophysiology and the principal investigator at Valley for the Praetorian Trial. “The S-ICD, because it does not involve a lead within the heart, may significantly reduce the likelihood of lead-related complications. This trial is the first attempt to compare the two types of ICDs in a randomized trial.”

In the PRAETORIAN trial, which originated at the Academic Medical Center in Amsterdam, the Netherlands, patients are randomly selected to receive either a traditional ICD or an S-ICD. Mark W. Preminger, M.D., director, implantable arrhythmia devices at Valley, enrolled the first patients in the United States into the study in February.

“The S-ICD is the world’s only subcutaneous ICD, and it represents a major step forward in the evolution of defibrillator technology,” Mittal said. “We are delighted to offer this advanced breakthrough in arrhythmia treatment to our Valley Hospital patients, and proud to be a leading participant in this important international trial.”

For more information: www.clinicaltrials.gov


Related Content

News | Cardiovascular Clinical Studies

September 8, 2022 — A clinical trial led by investigators from Brigham and Women’s Hospital has found that the long-term ...

Home September 08, 2022
Home
News | Cardiovascular Clinical Studies

August 17, 2022 — A study carried out by scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) ...

Home August 17, 2022
Home
News | Cardiovascular Clinical Studies

August 12, 2022 — Older adults with atrial cardiopathy (a major, often undetected cardiac cause of stroke) may be at ...

Home August 12, 2022
Home
News | Cardiovascular Clinical Studies

August 8, 2022 — Two years ago, University of Alabama at Birmingham researchers and colleagues reported that reductive ...

Home August 08, 2022
Home
News | Cardiovascular Clinical Studies

July 22, 2022 — BioSig Technologies, Inc. a medical technology company advancing electrophysiology workflow by ...

Home July 22, 2022
Home
News | Cardiovascular Clinical Studies

July 18, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that ...

Home July 19, 2022
Home
News | Cardiovascular Clinical Studies

July 15, 2022 — Imagine, if scientists had a map of the heart, so granular in its accuracy that it even profiled details ...

Home July 15, 2022
Home
News | Cardiovascular Clinical Studies

July 11, 2022 — Smoking traditional or non-combustible cigarettes while wearing a surgical mask results in a two-fold ...

Home July 12, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
Subscribe Now